Showing 2321-2330 of 5771 results for "".
- ImprimisRx to Introduce New Formulations at Cataract & Refractive Surgery Annual Meetinghttps://modernod.com/news/imprimisrx-to-introduce-new-formulations-at-cataract-refractive-surgery-annual-meeting/2476518/ImprimisRx announced its participation at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting to be held at the San Diego Convention Center in San Diego, May 3-7, 2019. At the conference, attendees will have the opportunity to meet with ImprimisRx representative
- Avedro Announces Comprehensive Educational Schedule at ASCRS Annual Meetinghttps://modernod.com/news/avedro-announces-comprehensive-educational-schedule-at-ascrs-annual-meeting/2476513/Avedro announced the inclusion of a wide range of corneal cross-linking and keratoconus scientific and educational programs at the 2019 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting held M
- Bausch + Lomb Announces Update From Antibiotic Resistance Monitoring in Ocular Microorganism (ARMOR) Studyhttps://modernod.com/news/bausch-lomb-announces-update-from-antibiotic-resistance-monitoring-in-ocular-microorganism-armor-study/2476512/Bausch + Lomb announced the results from nearly 10 years of the ARMOR (Antibiotic Resistance Monitoring in Ocular Microorganisms) surveillance study, presented at the ARVO meeting in Vancouver. Researchers also presented preliminary 2018 surveillance data on antibiotic resistance levels. Initiate
- Bausch + Lomb Announces New Scientific Analyses Featuring Surgical And Pharmaceutical Products Will Be Presented During ASCRShttps://modernod.com/news/bausch-lomb-announces-new-scientific-analyses-featuring-surgical-and-pharmaceutical-products-will-be-presented-during-ascrs/2476509/Bausch + Lomb announced that 26 new scientific analyses, including 23 podium presentations and three posters, will feature the company’s surgical and pharmaceutical products during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego from
- MeiraGTx Announces Upcoming Presentation on Achromatopsia Gene Therapy Candidate AAV-CNGA3 at ARVO 2019https://modernod.com/news/meiragtx-announces-upcoming-presentation-on-achromatopsia-gene-therapy-candidate-aav-cnga3-at-arvo-2019/2476504/MeiraGTx Holdings announced a preclinical poster on safety and efficacy of the company’s gene therapy product candidate AAV-CNGA3 for the treatment of patients with achromatopsia (ACHM) due to mutations in the CNGA3 gene will be presented at the Association for Research in Vision and Oph
- ReNeuron Announces Presentation of Updated Efficacy and Safety Data from Retinitis Pigmentosa Studyhttps://modernod.com/news/reneuron-announces-presentation-of-updated-efficacy-and-safety-data-from-retinitis-pigmentosa-study/2476502/ReNeuron Group announced updated positive preliminary results in the company’s ongoing phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2a part of the trial have demonstr
- Aerie Pharmaceuticals Announces Acceptance of Its IND Application for Sustained-Release Implant for Retinal Diseaseshttps://modernod.com/news/aerie-pharmaceuticals-announces-acceptance-of-its-ind-application-for-sustained-release-implant-for-retinal-diseases/2476498/Aerie Pharmaceuticals announced that the FDA has reviewed the investigational new drug (IND) application for AR-13503, a novel multi-kinase (Rho kinase/Protein kinase C (ROCK/PKC)) inhibitor sustained-release implant, and it is now in effect, allowing Aerie to initiate human studies in the treat
- Oxurion Announces Full Enrollment in its Phase 1 Trial Evaluating the Safety of its Plasma Kallikrein Inhibitor THR-149 for Treatment of DMEhttps://modernod.com/news/oxurion-announces-full-enrollment-in-its-phase-1-trial-evaluating-the-safety-of-its-plasma-kallikrein-inhibitor-thr-149-for-treatment-of-dme/2476492/Oxurion NV announced that it has completed enrollment of its phase 1 study of THR-149, a novel plasma kallikrein (PKal) inhibitor for the treatment of diabetic macular edema (DME). A total of 15 patients have been recruited. The study enrolled faster than anticipated and initial data will be rele
- Ivantis Announces Publication of Comparative MIGS Clinical Trial Resultshttps://modernod.com/news/ivantis-announces-publication-of-comparative-migs-clinical-trial-results/2476486/Ivantis, developer of the Hydrus Microstent, announced that the 12-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS) were accepted into the journal Ophthalmology, according to a company news release. COMPARE is the first prospective, multicenter, ra
- Bausch + Lomb Announces New Divisional Leadership in the UShttps://modernod.com/news/bausch-lomb-announces-new-divisional-leadership-in-the-us/2476487/Bausch + Lomb announced the appointment of new leadership in its Pharmaceuticals and Consumer Health Care divisions in the United States. Yolande Barnard, formerly the vice president, marketing and sales, U.S. Neurology, Bausch Health, will now serve as vice president and general manager,